Holen Sie sich die Stockscreener-App
10.66
2.47%
-0.27
Handel nachbörslich:
10.80
0.14
+1.31%
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Why ARS Pharmaceuticals Inc. stock could rally in 2025Trade Volume Report & AI Driven Stock Reports - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this weekWall Street Watch & Weekly Consistent Profit Watchlists - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatilityWeekly Investment Report & Weekly Stock Performance Updates - newser.com
Sentiment analysis tools applied to ARS Pharmaceuticals Inc.Earnings Summary Report & AI Enhanced Trading Alerts - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelinePortfolio Risk Report & High Return Trade Opportunity Guides - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Buy Signal & Fast Exit/Entry Strategy Plans - newser.com
Price action breakdown for ARS Pharmaceuticals Inc.Weekly Trade Summary & Community Consensus Trade Signals - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
ARS Pharmaceuticals (SPRY): Assessing Valuation After European Patent Win Secures Neffy Exclusivity Through 2039 - Sahm
How to track smart money flows in ARS Pharmaceuticals Inc.Market Trend Summary & Accurate Trade Setup Notifications - newser.com
ARS Pharmaceuticals (SPRY) Is Up 9.8% After Securing $250M Loan and European Patent Win – Has the Bull Case Changed? - Sahm
Epi Spray Maker Urges FDA to Require More Study of Epi Film - Allergic Living
Pattern recognition hints at ARS Pharmaceuticals Inc. upside2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals - Wilson Sonsini
ARS Pharmaceuticals' (SPRY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
ARS Pharmaceuticals Hits Day High with 7.55% Surge to $11.11 - Markets Mojo
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy - MarketScreener
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, - openPR.com
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini
ARS Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
ARS Pharma’s epinephrine nasal spray patent upheld in Europe By Investing.com - Investing.com Australia
ARS Pharma’s epinephrine nasal spray patent upheld in Europe - Investing.com
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals receives favorable decision from European Patent Office on patent related to neffy (epinephrine nasal spray) - MarketScreener
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire
EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 - Stock Titan
Knights of Columbus Asset Advisors LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
What drives ARS Pharmaceuticals Inc stock priceEmerging Market Stocks & Your Free Entry to Smart Investing Starts Here - earlytimes.in
ARS Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Uncovering a 205% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Is ARS Pharmaceuticals Inc. building a consolidation baseWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your ARS Pharmaceuticals Inc. exit2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on ARS Pharmaceuticals Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Janney Montgomery Scott LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Published on: 2025-10-05 03:09:06 - newser.com
Is ARS Pharmaceuticals Inc. stock a buy before product launchesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
A Look at ARS Pharmaceuticals’s Valuation Following Major $250M Funding for Neffy Commercial Growth - Sahm
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance
Why ARS Pharmaceuticals (SPRY) Is Up 7.8% After Securing $250M Loan and Japan Approval for neffy - Sahm
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - 富途牛牛
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
William Blair Expects Lower Earnings for ARS Pharmaceuticals - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 6.6%Here's Why - MarketBeat
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly - Reuters
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):